Boehringer/Pfizer Spiriva review
Executive Summary
Boehringer-Ingelheim/Pfizer's Spiriva (tiotropium) will be reviewed by FDA's Pulmonary-Allergy Drugs Advisory Committee Sept. 6. The NDA for the treatment of chronic obstructive pulmonary disease was submitted Dec. 13, 2001 (1"The Pink Sheet" Dec. 24, 2001, p. 18). The meeting will be at the Holiday Inn in Gaithersburg, Md., at 7:30 a.m. [To view a webcast/video broadcast of this meeting, visit FDAAdvisoryCommittee.com]...
You may also be interested in...
Pfizer Pregabalin NDA Will Include Anxiety Use; Filing Date Pushed To 2002
Pfizer's updated pregabalin NDA filing schedule calls for three initial indications - add-on epilepsy, neuropathic pain and generalized anxiety disorder - to be submitted in 2002
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.